LATITUDE Chrohns Disease Studies

Let's

navigate

Crohn's Disease

together

Let's

navigate

Crohn's Disease

together

Let's Navigate Crohn's Disease Together

If life with Crohn's disease feels like it revolves around constant planning, pain, and uncertainty, explore a different route with the LATITUDE CD Study.

Did You Know?

CD most commonly develops in people 20–30 years old, but it can develop in people of any age.1 That’s why researchers are seeking effective treatment options for people of all ages.
CD symptoms can be mild, but after the first year of diagnosis, up to 30% of people affected will have moderate to severe symptoms.2 Researchers are looking for ways to help them.
Flares can impact so much of daily life—outings with friends, what to eat, when to leave the house, and much more. We see it. Evidence suggests that 91% of people with CD have an impaired quality of life.3
There is a component of family history and genetics to getting Crohn’s disease, but there is no way to predict who gets it. If both parents have a type of inflammatory bowel disease, the risk for their children to develop Crohn's disease is about 35%.4
People of color are often delayed in receiving a Crohn’s disease diagnosis, which can lead to further complications.5 That’s why it’s important for people from all communities to be represented in clinical research.

Explore a different route for potential relief with the LATITUDE CD Study.

You may be able to participate in the LATITUDE CD Study if you:

Are 18–75 years old
Were diagnosed with Crohn's disease and are currently experiencing symptoms
Have tried at least 1 other treatment for your Crohn's disease that didn't work
Are interested in an investigational oral treatment

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

Qualified participants will receive all study-related medications and study-related care at no cost. Participants may be compensated for travel and expenses.

About the LATITUDE CD Study

The LATITUDE CD Study is evaluating the efficacy and safety of an investigational oral treatment for Crohn’s disease. Participants will receive the investigational treatment or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.  

Participants originally assigned to placebo who still have disease worsening after the 12-week induction phase will have the opportunity to switch to the investigational treatment. All study treatments will be given as oral pills.  

Neither participants nor the study staff will know if participants are receiving the investigational treatment or a placebo. Participants will attend up to 14 scheduled study visits (and any additional study visits if needed) over the course of about a year.  

© 2023–2024 Clinical Trial Media. All Rights Reserved.